Matheus Pessini Sousa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Matheus Pessini Sousa has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Caio Pereira Mueller
Universidade Federal do Paraná Curitiba PR Brasil Universidade Federal do Paraná, Curitiba, PR, Brasil
2 shared publications - Cléo Otaviano Mesa Júnior
Universidade Federal do Paraná Departamento de Medicina Interna Serviço de Endocrinologia e Metabologia (SEMPR) Curitiba PR Brasil Departamento de Medicina Interna, Serviço de Endocrinologia e Metabologia (SEMPR), Universidade Federal do Paraná, Curitiba, PR, Brasil
2 shared publications - Fabíola Yukiko Miasaki
Universidade Federal do Paraná Departamento de Medicina Interna Serviço de Endocrinologia e Metabologia (SEMPR) Curitiba PR Brasil Departamento de Medicina Interna, Serviço de Endocrinologia e Metabologia (SEMPR), Universidade Federal do Paraná, Curitiba, PR, Brasil
2 shared publications - Gisah Amaral de Carvalho
Universidade Federal do Paraná Departamento de Medicina Interna Serviço de Endocrinologia e Metabologia (SEMPR) Curitiba PR Brasil Departamento de Medicina Interna, Serviço de Endocrinologia e Metabologia (SEMPR), Universidade Federal do Paraná, Curitiba, PR, Brasil
2 shared publications - Hans Graf
Universidade Federal do Paraná Departamento de Medicina Interna Serviço de Endocrinologia e Metabologia (SEMPR) Curitiba PR Brasil Departamento de Medicina Interna, Serviço de Endocrinologia e Metabologia (SEMPR), Universidade Federal do Paraná, Curitiba, PR, Brasil
2 shared publications - Isabela Busto Silva
Universidade Federal do Paraná Departamento de Medicina Interna Serviço de Endocrinologia e Metabologia (SEMPR) Curitiba PR Brasil Departamento de Medicina Interna, Serviço de Endocrinologia e Metabologia (SEMPR), Universidade Federal do Paraná, Curitiba, PR, Brasil
2 shared publications
Latest Publications
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (6) , 1-6
Remission and relapse rates in Graves’ disease treated with methimazole: a 20-year retrospective cohort study
Objective: To evaluate remission and relapse rates in patients with Graves’ disease treated with methimazole and to identify clinical and laboratory predictors of these outcomes. Subjects and methods: We conducted a retrospective cohort study of 425 adult patients newly diagnosed with Graves’ disease at a single tertiary center between 2002 and 2022. All patients received methimazole for at least 12 months. Remission was defined as drug-free biochemical euthyroidism for 12 months or longer after therapy withdrawal. Univariate and multivariate [...] ABSTRACT Objective: To evaluate remission and relapse rates in patients with Graves’ disease treated with methimazole and to identify clinical and laboratory predictors of these outcomes. Subjects and methods: We conducted a retrospective cohort study of 425 adult patients newly diagnosed with Graves’ disease at a single tertiary center between 2002 and 2022. All patients received methimazole for at least 12 months. Remission was defined as drug-free biochemical euthyroidism for 12 months or longer after therapy withdrawal. Univariate and multivariate
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (6) , 1-6
Remission and relapse rates in Graves’ disease treated with methimazole: a 20-year retrospective cohort study
Objective: To evaluate remission and relapse rates in patients with Graves’ disease treated with methimazole and to identify clinical and laboratory predictors of these outcomes. Subjects and methods: We conducted a retrospective cohort study of 425 adult patients newly diagnosed with Graves’ disease at a single tertiary center between 2002 and 2022. All patients received methimazole for at least 12 months. Remission was defined as drug-free biochemical euthyroidism for 12 months or longer after therapy withdrawal. Univariate and multivariate [...] ABSTRACT Objective: To evaluate remission and relapse rates in patients with Graves’ disease treated with methimazole and to identify clinical and laboratory predictors of these outcomes. Subjects and methods: We conducted a retrospective cohort study of 425 adult patients newly diagnosed with Graves’ disease at a single tertiary center between 2002 and 2022. All patients received methimazole for at least 12 months. Remission was defined as drug-free biochemical euthyroidism for 12 months or longer after therapy withdrawal. Univariate and multivariate
- Open Access
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 72 (2) , 1-6
The decline of iodine therapy in the treatment of Graves’ disease in a hospital center: a 20-year analysis
Objective: To evaluate and describe the changes in the therapeutic approach to Graves’ disease at a tertiary hospital center over a 20-year period, with an emphasis on the frequency of prescription and the timing of radioactive iodine indication. Subjects and methods: We conducted a retrospective analysis of data from medical records of patients recently diagnosed with Graves’ disease (GD) and followed up at a single institution during two consecutive periods: Group A diagnosed between 2002 and 2010, and Group [...] ABSTRACT Objective: To evaluate and describe the changes in the therapeutic approach to Graves’ disease at a tertiary hospital center over a 20-year period, with an emphasis on the frequency of prescription and the timing of radioactive iodine indication. Subjects and methods: We conducted a retrospective analysis of data from medical records of patients recently diagnosed with Graves’ disease (GD) and followed up at a single institution during two consecutive periods: Group A diagnosed between 2002 and 2010, and Group
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 72 (2) , 1-6
Open AccessThe decline of iodine therapy in the treatment of Graves’ disease in a hospital center: a 20-year analysis
Objective: To evaluate and describe the changes in the therapeutic approach to Graves’ disease at a tertiary hospital center over a 20-year period, with an emphasis on the frequency of prescription and the timing of radioactive iodine indication. Subjects and methods: We conducted a retrospective analysis of data from medical records of patients recently diagnosed with Graves’ disease (GD) and followed up at a single institution during two consecutive periods: Group A diagnosed between 2002 and 2010, and Group [...] ABSTRACT Objective: To evaluate and describe the changes in the therapeutic approach to Graves’ disease at a tertiary hospital center over a 20-year period, with an emphasis on the frequency of prescription and the timing of radioactive iodine indication. Subjects and methods: We conducted a retrospective analysis of data from medical records of patients recently diagnosed with Graves’ disease (GD) and followed up at a single institution during two consecutive periods: Group A diagnosed between 2002 and 2010, and Group